Expert Perspectives: Overcoming the Hurdles: Advances in the Management of Hemophilia

To participate in this activity, please:

The therapeutic landscape of hemophilia continues to evolve at a rapid pace, providing clinicians and patients new opportunities to select treatment to address individual needs and characteristics. In this fast-moving, 1-hour accredited activity, Craig Kessler, MD, and Guy Young, MD, share their thoughts and experience with clotting factor concentrates, recombinant factor, factor VIII mimetics, rebalancing agents, and gene therapies. The safety and efficacy of late-phase investigational products are also discussed as these agents have the potential to address unmet needs and further transform patient care.

Course Credit:

1 AMA PRA Category 1 CreditTM

Dates:

Opens: 2024-09-27
Closes: 2025-09-27

Target Audience:

Hematologists, hematologist-oncologists, hematology nurse practitioners, hematology physician associates, and pharmacists involved in the management of patients diagnosed with hemophilia.

This activity is supported by an independent educational grant from Novo Nordisk.

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Sarah Rockwell, PharmD, BCOP (Medical Writer)

Advisory Board: CTI Biopharma, Janssen

Consultant: Genentech


Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Craig M. Kessler, MD

    SOM Clinical Scholar Track–Professor
    Professor of Oncology
    Professor of Medicine and Pathology
    Director, Division of Coagulation, Department of Laboratory Medicine
    Director, Therapeutic and Cellular Apheresis Unit
    Director, Comprehensive Hemophilia and Thrombophilia Treatment Center
    Georgetown University Medical Center
    Washington, DC

  • Guy Young, MD

    Director, Hemostasis and Thrombosis Center
    Director, Clinical Coagulation Laboratory
    Cancer and Blood Disorders Institute
    Children's Hospital Los Angeles
    Professor of Pediatrics
    University of Southern California Keck School of Medicine
    Los Angeles, California

Learning Objectives

  • Assess safety and management considerations of novel therapies for the treatment of hemophilia, including extended half-life products, bispecific antibodies, and rebalancing agents
  • Compare the mechanisms of action and dosing for novel and emerging therapies in hemophilia
  • Develop treatment and monitoring plans for patients with hemophilia using evidence-based recommendations

Faculty Disclosures

Craig M. Kessler, MD

Advisory Board: BioMarin, CSL Behring, Genentech, Novo Nordisk, Regeneron, Sanofi, Takeda

Data Monitoring Safety Board: Bayer, Octapharma


Guy Young, MD

Consultant: BioMarin, CSL Behring, Genentech/Roche, HEMA Biologics, Novo Nordisk, Octapharma, Pfizer, Sanofi, Takeda